GENETIC TESTING FOR KIDNEY DISEASES IN EMBRYOS FROM IN VITRO FERTILIZATION

Analysis provides insights on 25-year trends

Highlights

- A recent analysis examines data from over the past 25 years concerning couples’ use of genetic testing for kidney diseases in embryos from in vitro fertilization.
- The analysis provides the first report on the types of genetic kidney diseases tested in this way, how often these tests result in live births of unaffected children, and what reasons couples cite for not undergoing testing.

Washington, DC (August 27, 2020) — Preimplantation genetic testing (PGT)—a technique used to identify genetic defects in embryos created through in vitro fertilization before pregnancy—helps prospective parents to prevent passing on disease-causing mutations to their children. An analysis in an upcoming issue of CJASN provides a clinical overview of the past 25 years of PGT for kidney diseases in the Netherlands.

The analysis, which was conducted by a team led by Albertien M. van Eerde, MD, PhD and Rozemarijn Snoek, MD (University Medical Center Utrecht), included information on couples counselled on PGT for monogenic kidney diseases (which are caused by mutations in a single gene). The procedures were performed through the Dutch PGT consortium - with as lead center Maastricht UMC+ - from January 1995 until June 2019. Most procedures for kidney disease were performed in the last decade. The PGT procedure in the Netherlands is part of reimbursed healthcare.

“PGT is a relatively recent addition to the options couples at risk for having a child with monogenic kidney disease have,” said Dr. van Eerde. “There was no literature on the range of indications PGT has been performed for, success rates, and reasons for opting out after having been informed.”

The team found that the number of couples counselled on PGT for monogenic kidney disease steadily increased over time. Ninety-eight couples were counselled regarding PGT, of whom 53% opted to proceed with testing, 38% chose not to proceed, and 9% had not yet decided whether to proceed as of June 2019.

The most frequent indications for testing were autosomal dominant polycystic kidney disease (38%), Alport syndrome (26%), and autosomal recessive polycystic kidney disease.
disease (9%). Also, 45% of procedures were performed for adult onset kidney disease, with an increase to over 50% in recent years. Of couples with at least one PGT cycle with egg retrieval, 65% experienced one or more live births of a child without kidney disease.

The authors noted that as the number of kidney diseases for which a monogenic cause can be identified continues to grow, it becomes increasingly important to counsel patients on their reproductive options to enable them to make informed choices.

“Choosing how to start a family can be a complex decision if one has a genetic disease. Through PGT, a genetically unaffected pregnancy can be established, through an in vitro fertilization procedure,” said Dr. van Eerde. “Insights from our study may help doctors in informing patients with monogenic kidney disease who wish to start a family, and allow for adequate counselling.”

An accompanying editorial noted that in the absence of insurance coverage, costly genetic services are primarily available to those who can pay out of pocket, and limits in the coverage of assisted reproductive technology disproportionately burden racially marginalized groups. The authors stressed that there is a need to address moral questions about the acceptable use of PGT, and to ensure access based on need rather than ability to pay. “Payers, including government programs, may be more likely to include coverage of preimplantation genetic testing if professional organizations offer stringent guidelines for its use that have the dual goal of preventing the birth of children with serious disease while supporting equitable access,” they wrote.

A Patient Voice editorial also accompanies the study.

Study co-authors include Marijn F. Stokman, MD, PhD, Klaske D. Lichtenbelt, MD, PhD, Theodora C. van Tilborg, MD, PhD, Cindy E. Simcox, Aimée D.C. Paulussen, PhD, Jos C.M.F. Dreesen, Franka van Reekum, MD, A. Titia Lely, MD, PhD, Prof. Nine V.A.M. Knoers, MD, PhD, and Christine E.M. de Die-Smulders, MD, PhD.

Disclosures: The authors reported no financial disclosures.

The article, titled “Preimplantation Genetic Testing for Monogenic Kidney Disease,” will appear online at http://cjasn.asnjournals.org/ on August 27, 2020, doi: ***.


The Patient Voice editorial, titled “Genetic Testing Is Beneficial To the Entire Family,” will appear online at http://cjasn.asnjournals.org/ on August 27, 2020, doi: ***.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.

# # #